$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Medical drugs
Medical drugs
Medical drugs-Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Contraindications and unsuitable groups for Lynparza
2026-02-01 22:25:32
Check Details
Detailed explanation of reimbursement scope and reimbursement conditions for Venetoclax
2026-02-01 22:25:32
Check Details
The launch time and approval progress of Asciminib in China
2026-02-01 22:25:32
Check Details
Analysis of the efficacy and safety of the second phase clinical trial of ritexitinib (Lefenox)
2026-02-01 22:25:32
Check Details
Efficacy and clinical data analysis of sparsentan (sparsentan) in the treatment of IgA nephropathy
2026-02-01 22:25:32
Check Details
Which diseases can Ixazomib (Enleri) be used to treat and its efficacy evaluation?
2026-02-01 22:25:32
Check Details
Analysis of domestic prices and reference costs of Lurbinectedin in 2025
2026-02-01 22:25:32
Check Details
What are the common side effects of furmonertinib, their occurrence time and countermeasures?
2026-02-01 22:25:32
Check Details
Correct usage and safety instructions for taking ensifentrine-Ohtuvayre
2026-02-01 22:25:32
Check Details
What you need to know about the effects, potential hazards and risk prevention of Roaccutane (isotretinoin) soft capsules
2026-02-01 22:25:32
Check Details
What is doxorubicin? Introduction to antitumor drug classification and clinical application
2026-02-01 22:25:32
Check Details
Will taking everolimus (Afinitor) for 15 days increase the risk of cancer?
2026-02-01 22:25:32
Check Details
1
2
...
2160
2161
2162
2163
2164
2165
2166
...
2439
2440
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
AbbVie’s TEPKINLY (epcoritamab) Plus R² Granted EU Approval for Relapsed/Refractory Follicular Lymphoma
2
Global Oncology Update: Breakthroughs in Advanced Cancer Survival and Novel Therapies
3
Phase 1 Study Progress of Ceralasertib in Combination with Durvalumab for Advanced NSCLC and HNSCC
4
Global Breakthroughs in Cancer Drugs and Advanced Treatment Technologies
5
ROS and Cancer: The Potential of Natural Antioxidants
6
SKYSCRAPER-02C Study: New Hope for Extensive-Stage Small Cell Lung Cancer Treatment
7
LPCAT3: The Key Player in MASH Progression to Hepatocellular Carcinoma
8
Breztri Aerosphere Approved by US FDA for Maintenance Treatment of Asthma in Patients Aged 12 Years and Older
9
Datopotamab Deruxtecan as First-Line Treatment for Advanced Triple-Negative Breast Cancer: Full Interpretation of the Phase III TROPION-Breast02 Trial
10
Olaparib Plus Pembrolizumab Maintenance Therapy for Metastatic Pancreatic Cancer: Findings from the POLAR Phase II Basket Trial
11
From Causes to Treatments—Exploring Medical Breakthroughs
12
IRX4 Transcription Factor: New Research Insights on Colorectal Cancer Treatment Targets